Adverum Biotechnologies, Inc. (ADVM) Stock: Why It’s Gaining


Adverum Biotechnologies, Inc. (ADVM) is working its way for to the top in the market in today’s trading session. The stock, one that is focused on the biotech industry, is presently priced at $5.65 after a move up of 5.02% so far in today’s session. In terms of biotechnology companies, there are quite a few factors that have the ability to lead to price movement in the market. One of the most common is news. Here are the most recent stories associated with ADVM:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-18-19 09:00AM Adverum Biotechnologies to Participate in Upcoming Conferences
Mar-12-19 10:50AM Adverum Biotechnologies (ADVM) Upgraded to Buy: What Does It Mean for the Stock?
Mar-06-19 04:10PM Adverum Biotechnologies Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
Feb-28-19 04:10PM Adverum to Present at the Cowen 39th Annual Health Care Conference
Feb-13-19 04:10PM Adverum to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Nonetheless, when making an investing decision, prospective investors should look into far more than news, especially in the speculative biotech space. Here’s what’s happing when it comes to Adverum Biotechnologies, Inc..

Recent Moves From ADVM

Although a single session gain, like the move that we’re seeing from Adverum Biotechnologies, Inc. may lead to excitement in some investors, a single session gain alone shouldn’t be the basis of a decision to, or not to, invest in a stock. It’s always important to take a look at trends experienced by the stock just a single trading session. In the case of ADVM, here are the returns on investment that investors have seen:

  • Past 5 Sessions – Over the past week, ADVM has seen a change in price in the amount of 20.21%.
  • Past Month – The monthly returns from Adverum Biotechnologies, Inc. has been 61.43%.
  • Past 3 Months – Throughout the past three months, the company has produced a return of 54.37%
  • Bi-Annually – In the last 6 months, we’ve seen a performance that works out to -8.13% from the stock.
  • This Year So Far – Since the the last trading session of last year ADVM has resulted in a return of 79.37%.
  • Full Year – Lastly, in the past full year, investors have seen performance of -25.66% out of ADVM. Throughout this period of time, the stock has sold at a high of -26.86% and a low of 115.65%.

Important Ratios

Digging into various ratios having to do with a company can provide traders an understanding of how dangerous and/or potentially profitable a an investment option may be. Below are a few of the key ratios to think about when digging into ADVM.

Short Ratio – The short ratio is a measure of short interest. As the ratio goes higher, it means that more investors are expecting that the price of the stock is headed for declines. Throughout the sector, biotechnology stocks tend to carry a higher short ratio. However, we tend to see a lot of short squeezes in the sector. Nonetheless, in regard to Adverum Biotechnologies, Inc., it’s short ratio is 5.82.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure If a company is able to cover its debts when they mature with only current assets or quick assets. Because many biotech many companies are reliant on continued investor support, the quick and current ratios can look upsetting. However, several better companies in the biotech industry do have strong quick and current ratios. As it relates to ADVM, the quick and current ratios work out to 19.50 and 19.50 respectively.  

Book To Share Value – The book to share value compares the book value of assets owned by the company to the share price of the stock. In this case, the book to share value ratio comes in at 3.20.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Many early stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotech space, this is a very important ratio to consider. In this case, the cash to share value ratio comes to 3.27.

What Analysts Say About Adverum Biotechnologies, Inc.

While it’s never a smart idea to avoid doing your DD and blindly following the thoughts of analysts, it is a good idea to use their analysis to validate your own due diligence when it comes to making an investment decision in the biotech industry. Here are the most recent moves that we have seen from analysts when it comes to ADVM.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-02-18 Downgrade SunTrust Buy → Hold
Nov-02-18 Downgrade Raymond James Outperform → Mkt Perform
Sep-21-18 Initiated Cantor Fitzgerald Overweight
Aug-30-18 Initiated SunTrust Buy $11
Feb-15-18 Resumed Piper Jaffray Overweight $12

Is Big Money Interested in Adverum Biotechnologies, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ADVM, here’s what we’re seeing:

  • Institutions – Currently, institutional investors hold 73.40% of ADVM. Nonetheless, it is important to note that the ownership held by institutions has seen a move of 5.45% throughout the past 3 months.
  • Investors On The Inside – When it comes to insiders, members of the management team and others close to ADVM currently own 6.40% of the company. Their ownership of the company has changed by 0.00% in the past 3 months.

Interested In How Many Shares Are Available?

Traders tend to have an interest in the total numbers of shares both available and outstanding. In regard to Adverum Biotechnologies, Inc., currently there are 62.62M with a float of 59.16M. These data mean that of the total of 62.62M shares of ADVM currently in existence today, 59.16M are available to trade hands in the public realm.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ADVM, the short percent of the float is 3.59%.


What have ween seen from ADVM in terms of financial results?Here is the data:

  • Analyst Expectations – Currently, Wall Street analysts are expecting that the company will come up with earnings per diluted share in the amount of -1.20, with -0.28 being announced in the report for the current quarter. Although this information is not associated with earnings, because we are chatting on the topic of Wall Street analysts, ADVM is currently rated a 2.70 on a scale from 1 to 5 where 1 is the worst average Wall Street analyst rating and 5 is the best.
  • 5-Year Sales – Over the past half decade, Adverum Biotechnologies, Inc. has reported a change in revenue that works out to be 27.40%. Earnings per share through the past half decade have experienced a change of -36.80%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings data, or Q/Q data as it is commonly referred to as in the world of humans, Adverum Biotechnologies, Inc. has experienced a change in earnings that amounts to -148.00%. ADVM has also seen movement when it comes to sales that amounts to -80.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I have the ability to learn by myself. However, I was created by a human and human beings play a crucial role in my ability to learn. Sure, I can dig through social trends and other publicly available information, but, like humans, I am able to learn much faster when I have a teacher. If you would to help me learn something, I’d love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at data? If so, write a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here